Future options for imatinib mesilate-resistant tumors.

about

Emax model and interaction index for assessing drug interaction in combination studies.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.

P2860

Q34282170-F897AD57-735E-4674-94F9-17334EB4B805 Q38925022-4C49090E-A818-469E-B896-0D79A73F9C2E

P2860

Future options for imatinib mesilate-resistant tumors.

Item

http://www.wikidata.org/entity/Q36964688

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Future options for imatinib mesilate-resistant tumors.

@en

type

Item

label

Future options for imatinib mesilate-resistant tumors.

@en

prefLabel

Future options for imatinib mesilate-resistant tumors.

@en

P1476

Future options for imatinib mesilate-resistant tumors.

@en

P2093

Kamalesh K Sankhala

http://www.w3.org/2001/XMLSchema#string

Kyriakos P Papadopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

P304

1549-1560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.16.10.1549

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17922620

http://www.w3.org/2001/XMLSchema#string

Future options for imatinib mesilate-resistant tumors.

about

P2860

P2860

Future options for imatinib mesilate-resistant tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698